Journal of Neurology, Neurosurgery and Psychiatry
is a leading international journal publishing the latest research and reviews on all areas of neurological sciences.
Impact Factor: 11
Citescore: 15.9
All metrics >>
Authors
JNNP accepts submissions of a wide range of article types, including review articles and original research.
The Author Information section provides specific article requirements to help you turn your research into an article suitable for JNNP.
Information is also provided on editorial policies and open access.
Latest Articles
BNPA Lifetime Achievement Award:
Placebo, suggestion and FND - interactions and clues to pathophysiology15 November 2023
The BNPA Members' Platform Presentations:
19 Direct neural recordings from human bed nucleus of stria terminalis link alpha activity in empathy and affect evaluation tasks with depression severity15 November 2023
The BNPA Members' Platform Presentations:
19 Dimensions of interoception in people with epilepsy and people with functional non-epileptic seizures15 November 2023
The BNPA Members' Platform Presentations:
20 Reflexive downregulation of memory systems in dissociative amnesia: a case series15 November 2023
Most Read Articles
Neuropsychiatry:
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis10 July 2023
General neurology:
Multidisciplinary consensus guideline for the diagnosis and management of spontaneous intracranial hypotension5 May 2023
Editor's Choice
Multiple sclerosis:
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial6 July 2023
Epilepsy:
Risk-conferring HLA variants in an epilepsy cohort: benefits of multifaceted use of whole genome sequencing in clinical practice26 June 2023
Cerebrovascular disease:
Endovascular treatment for large-core ischaemic stroke: a meta-analysis of randomised controlled clinical trials14 July 2023
COVID-19
Multiple sclerosis:
Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels26 October 2023
Multiple sclerosis:
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study19 October 2023
Multiple sclerosis:
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses25 April 2023
PostScript:
Correspondence on functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines7 April 2023
Altmetrics
Podcasts
Featured Video
Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease
Repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. However, several factors should be considered before designing future clinical trials. These include targeting of appropriate patient subgroups and understanding the dose effects of individual drugs and their interactions with other treatments to minimise risks and maximise therapeutic effects.
Find out moreRelated Journals
